Brief: Epygen Biotech Reports Funding from India Government for Development of COVID-19 Vaccine
13/04/2022 14:15
April 13 (Reuters) - Dyadic International Inc DYAI.O :
* EPYGEN BIOTECH ANNOUNCES FUNDING FROM INDIA GOVERNMENT FOR
DEVELOPMENT OF A COVID-19 VACCINE USING DYADIC’S LICENSED C1
PROTEIN PRODUCTION PLATFORM
* DYADIC INTERNATIONAL INC - FUNDING EARMARKED TO SUPPORT
PHASE 1
AND 2 CLINICAL TRIALS OF EPYGEN'S COVID-19 VACCINE CANDIDATE
Source text for Eikon: ID:nGNX8CvNST
Further company coverage: DYAI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dyadic International
See all newsDyadic International Inc reports results for the quarter ended June 30 - Earnings Summary
Dyadic International Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Dyadic International - Develops C1 Cell Lines And Manufactures Bundibugyo Ebolavirus Antigens Within 15 Days
Brief: Dyadic Announces Continued Listing On The Nasdaq Capital Market
Brief: Dyadic And Scripps Research Collaborate On Rapid-Response Hantavirus Antibody And Vaccine Development